Skip to main content
. Author manuscript; available in PMC: 2009 May 4.
Published in final edited form as: J Neurovirol. 2006 Dec;12(6):492–500. doi: 10.1080/13550280601064798

Figure 6.

Figure 6

DAMGO prevents CXCL12-induced neuroprotection. Cortical neurons were treated with DAMGO (24 h) and subsequently exposed to NMDA (100 μM) and/or CXCL12 (20 nM) as detailed in the text. Results from three independent experiments with 10μMDAMGO are reported in A (** P < .001versus respective control; ˆˆP < .001 versus NMDA alone). Data shown in B include two additional experiments where neurons were exposed to DAMGO (both 1 and 10 μM) in the presence of the MOR-specific antagonist CTAP—added to the cultures before addition of DAMGO and maintained during DAMGO treatment—and BDNF, which was used as a control (** P < .001 versus NMDA alone). Each experiment was run in triplicate (i.e., three coverslips/treatment).